April 07, 2026 18:54 ET  | Source: AliveCor Inc. MOUNTAIN VIEW, Calif., April 07, 2026 (GLOBE NEWSWIRE) — AliveCor, the global leader in AI-powered cardiology, today announced the regulatory registration of its Kardia™ 12L electrocardiogram (ECG) System powered by KAI™ 12L AI technology in Vietnam, marking an important step toward expanding AI-enabled cardiac diagnostics across Southeast Asia. […]

Rigorous training and certification gives clinicians a validated pathway to AI-enabled cardiac POCUS proficiency April 07, 2026 11:24 ET  | Source: Inteleos, Inc. ROCKVILLE, Md. and BORDEAUX, France, April 07, 2026 (GLOBE NEWSWIRE) — HeartFocus, the AI-enabled cardiac imaging software developed by data-driven medtech company DESKi, today announced a partnership with Inteleos® through its Point-of-Care Ultrasound (POCUS) Certification

April 07, 2026 09:00 ET  | Source: Saladax Biomedical, Inc. Bethlehem, PA, April 07, 2026 (GLOBE NEWSWIRE) — Saladax Biomedical, Inc., a leader in therapeutic drug monitoring (TDM) diagnostics for psychiatry and oncology, today announced a distribution agreement with Thermo Fisher Scientific to expand global access to high-quality TDM assays that support clinicians in optimizing patient outcomes.

AI-enhanced suite of solutions features new and improved technology to empower efficiency, confidence and quality April 07, 2026 07:00 ET  | Source: Fortrea Holdings Inc Highlights: DURHAM, N.C., April 07, 2026 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE), a leading global clinical research organization (CRO), today unveiled Fortrea Intelligent Technology™(FIT), a suite of innovative technology solutions designed to transform clinical trial

April 06, 2026 09:00 ET  | Source: Egg Medical, Inc. MINNEAPOLIS, April 06, 2026 (GLOBE NEWSWIRE) — Egg Medical announces the launch of EggNest™ Complete Flex, a groundbreaking advancement in radiation protection that enables clinicians to safely work apron-free or with ultralight lead aprons—without the need for construction, structural modifications or procedural downtime. The first live case

April 02, 2026 07:10 ET  | Source: Adagene Inc. SAN DIEGO and SUZHOU, China, April 02, 2026 (GLOBE NEWSWIRE) — Adagene Inc. (“Adagene” or the “Company”) (Nasdaq: ADAG), a company committed to transforming the discovery and development of novel antibody-based therapies, today announced the pricing of its underwritten public offering of 18,666,000 American depositary shares, or ADSs, each representing

April 02, 2026 07:01 ET  | Source: Adagene Inc. Phase 1 study of INCA33890 and muzastotug expected to begin in 2026 in 3L MSS CRC patients with and without liver metastases Study will be sponsored and conducted by Incyte; Adagene to provide clinical supply of muzastotug Collaboration provides additional validation of muzastotug as a potential backbone therapy for

April 02, 2026 07:00 ET  | Source: Adagene Inc. Dose-Dependent Efficacy Results: As of the latest data cut, muzastotug achieved a 31% (8/26) confirmed overall response rate (ORR) in the combined 20 mg/kg dose cohorts, showing a clear improvement over the 13% ORR (5/39) in the combined 10 mg/kg dose cohorts Extended Durability: Median duration of response (mDOR)

April 01, 2026 17:00 ET  | Source: Adagene Inc. In 2025, muzastotug showed 29% confirmed overall response rate (ORR) among 21 patients with MSS CRC in the 20 mg/kg dose cohorts Median overall survival (OS) for the 10 mg/kg cohorts was 19.4 months, with a median follow-up of 17.8 months  4% overall discontinuation rate, no dose limiting toxicities,

April 01, 2026 06:00 ET  | Source: Zymeworks Inc. VANCOUVER, British Columbia, April 01, 2026 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced the appointment of Ms. Kristin Stafford as Chief Financial Officer, effective April 1, 2026.

April 01, 2026 02:40 ET  | Source: AskBio Inc. (AskBio) Durham, N.C., April 01, 2026 (GLOBE NEWSWIRE) — AskBio Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today announced that the randomization of the last participant was completed earlier this year for GenePHIT, its Phase 2 clinical trial

March 31, 2026 02:45 ET  | Source: Standing Ovation PRESS RELEASE Standing Ovation raises $34.2 million to scale up its breakthrough technology for producing dairy proteins through precision fermentation, offering a sovereign and sustainable response to the surge in global demand for protein Paris, 31 March 2026 – Standing Ovation, a French precision fermentation pioneer producing next-generation proteins,

March 30, 2026 08:00 ET  | Source: Teva Pharmaceutical Industries Ltd TEL AVIV, Israel and PARSIPPANY, N.J., March 30, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced three milestones in its biosimilar portfolio, demonstrating continued momentum in the advancement of its Pivot to Growth strategy. The United States (U.S.) Food and

March 30, 2026 06:00 ET  | Source: Zymeworks Inc. VANCOUVER, British Columbia, March 30, 2026 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to

Indira IVF and Abu Ghosh Fertility Group join the Nucleus IVF+ Network, as families seek a more complete picture of their future child’s health.  March 26, 2026 10:05 ET  | Source: Nucleus Genomics Inc. NEW YORK, March 26, 2026 (GLOBE NEWSWIRE) — Nucleus Genomics today announced joint ventures with Indira IVF, India’s largest IVF service provider, and Abu Ghosh Fertility